泰尔米沙坦增强了人肝细胞系中ITE诱导的基碳化合物受体活性
Jiun Hsu1, Hsiao-Ho Fang2, Jyan-Gwo Joseph Su3
1National Taiwan University Hospital Yunlin Branch, Yunlin, 640203, Taiwan, ROC.
Archives of toxicology
|October 31, 2024
概括
泰尔米沙坦是一种血管激素受体阻断剂,作为一种基碳化合物受体 (AhR) 激动剂. 它增强了CYP1A1的表达和与ITE的协同作用,这可能解释了其在慢性病中对脏的保护作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 泰尔米沙坦是一种血管激素受体阻断剂 (ARB),用于高血压,具有已知的心脏保护和保护作用.
- 基碳化合物受体 (AhR) 是一个信号通路,与慢性病进展有关.
- 细胞染色体P450 (CYP) 1A1是已知的AhR信号的目标基因.
研究的目的:
- 调查特尔米沙坦是否调节AhR信号传递.
- 探索telmisartan,其内源性配体ITE和AhR之间的相互作用.
- 阐明特尔米沙坦脏保护作用的潜在机制.
主要方法:
- 评估telmisartan对肝脏细胞系中CYP1A1促进体活性,mRNA和蛋白质表达的影响.
- 使用AhR抗剂 (CH-223191) 和AhR信号缺陷突变细胞来确认AhR调解.
- 评估telmisartan诱导AhR核转位和转录活性的能力.
- 检查telmisartan和ITE对CYP1A1表达的协同作用.
主要成果:
- 泰尔米沙坦显著增强了CYP1A1促进剂活性和基因/蛋白质表达,以剂量依赖的方式.
- 这些效应取决于AhR信号传递,这得到了对抗细胞和突变细胞研究的证实.
- 泰尔米沙坦诱导了AhR核转位和转录活动,将其确定为AhR激动剂.
- 泰尔米沙坦与ITE在促进CYP1A1表达方面表现出协同作用,特别是在AHR过度表达的细胞中.
结论:
- 泰尔米沙坦作为一种阿里碳化合物受体 (AhR) 激动剂.
- 泰尔米沙坦与内源的AhR配体ITE协同作用,以增强AhR通路的激活.
- 这些发现为telmisartan在慢性脏疾病中的脏保护作用的分子机制提供了新的见解.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391